Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, Massachusetts that was founded in 2013 by Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, and Thomas F. Gajewski. The company is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.
Products
JTX-2011
Jounce's lead product candidate is JTX-2011, a monoclonal antibody that binds to and activates the Inducible T-Cell Co-Stimulator (ICOS), a protein on the surface of certain T-cells that is believed will stimulate an immune response against a patient's cancer. It is intended to treat solid tumors as a single agent and in combination with other therapies. JTX-2011 is being evaluated in Phase 2 clinical trials.
JTX-8064
Another product candidate in Jounce's pipeline is JTX-8064. It is the company's lead Beyond T-cell program aimed at disrupting the interaction of targets on tumor-associated macrophages (TAMs) to skew the composition of macrophages within the tumor from immune-suppressing to immune-activating. Jounce is conducting IND enabling studies for this product.
JTX-4014
The third product in Jounce's pipeline is JTX-4014, another T-Cell targeting immunotherapy. The company filed its IND application in September 2018 and received approval to move to Phase 1 clinical trials in October 2018.
Partnerships
Celgene
In July 2016, Jounce entered into a collaboration with Celgene Corporation, which includes options to JTX-2011 and up to four early-stage programs to be selected from a defined pool of B cell, T regulatory cell, and tumor associated macrophage targets emerging from Jounce's Translational Science Platform and an additional option to equally share a checkpoint immuno-oncology program.
Funding
Series A
On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.
Series B
On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.
Timeline
Series B
On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.
Series A funding round
On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.
People
Allison Nance
VP, Regulatory Affairs & Quality Assurance
Anna L. Barry
Senior VP, General Counsel & Secretary
Dishant Shah
Employee
Drew Pardoll
Founder
Elizabeth Trehu
Chief Medical Officer
Hugh Cole
Chief Business Officer & Head of Corporate Development
James P. Allison
Founder
Kim Drapkin
CFO
Louis M. Weiner
Founder
Michael Woodbury
Employee
Padmanee Sharma
Founder
Richard Murray
President & CEO
Robert Schreiber
Founder
Stephen Farrand
Chief Technical Officer
Ted Harding
VP, Human Resources
Thomas F. Gajewski
Founder
Further reading
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-Generation Immuno-Oncology Therapies for Patients with Cancer
Jounce Therapeutics
Web
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
Jounce Therapeutics, Inc.
Web
Documentaries, videos and podcasts
Companies